UPDATE 1-Gilead third-quarter Sovaldi sales dip, but net profit triples
October 28, 2014 at 17:21 PM EDT
Oct 28 (Reuters) - Gilead Sciences Inc, maker of $84,000 hepatitis C drug Sovaldi, on Tuesday said third quarter net profit more than tripled and product sales doubled, despite a dip in Sovaldi sales as doctors and patients awaited a recently approved combination pill.